The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...
With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare ...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
Recently published work in the Journal of Endocrinological Investigation and Nature’s Scientific Reports demonstrates the advantages of a new method using DSI’s HD-XG implantable glucose device and...
These joint publications illustrate the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics dev...